Swedish biotechnology company Cantargia AB (STO:CANTA) on Friday reported promising new data from the ongoing CAN10 phase 1 clinical study.

All 68 participants receiving a single dose of CAN10 or placebo showed good safety and encouraging biomarker results.

Notably, a single dose of CAN10 has been shown to effectively block IL-1 and IL-36 signalling in the blood for at least one week, achieving key study endpoints. This strengthens the potential of CAN10's unique mechanism of action for treating autoimmune and inflammatory diseases.

The multi-dose portion of the trial is ongoing.